Business Description
HOOKIPA Pharma Inc
NAICS : 325412
SIC : 2834
ISIN : US43906K1007
Description
HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 17.85 | |||||
| Equity-to-Asset | 0.56 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | -0.09 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -3.21 | |||||
| Beneish M-Score | -2.93 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -34.3 | |||||
| 3-Year EBITDA Growth Rate | 18.4 | |||||
| 3-Year EPS without NRI Growth Rate | 24.5 | |||||
| 3-Year FCF Growth Rate | 25.9 | |||||
| 3-Year Book Growth Rate | -44.3 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 61.26 | |||||
| 9-Day RSI | 60.77 | |||||
| 14-Day RSI | 59.76 | |||||
| 6-1 Month Momentum % | 71.85 | |||||
| 12-1 Month Momentum % | -33.62 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.5 | |||||
| Quick Ratio | 3.5 | |||||
| Cash Ratio | 2.79 | |||||
| Days Sales Outstanding | 30.74 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -49.2 | |||||
| Shareholder Yield % | -52.56 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -366.31 | |||||
| Net Margin % | -405.29 | |||||
| FCF Margin % | -306.44 | |||||
| ROE % | -84.41 | |||||
| ROA % | -47.99 | |||||
| ROIC % | -177.12 | |||||
| ROC (Joel Greenblatt) % | -398.8 | |||||
| ROCE % | -63.07 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 4.53 | |||||
| PB Ratio | 1.01 | |||||
| Price-to-Tangible-Book | 1.01 | |||||
| EV-to-EBIT | 0.27 | |||||
| EV-to-EBITDA | 0.28 | |||||
| EV-to-Revenue | -1.07 | |||||
| EV-to-Forward-Revenue | 0.06 | |||||
| EV-to-FCF | 0.35 | |||||
| Price-to-Net-Current-Asset-Value | 1.21 | |||||
| Price-to-Net-Cash | 2 | |||||
| Earnings Yield (Greenblatt) % | 370.37 | |||||
| FCF Yield % | -67.83 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers